Literature DB >> 2013423

Natural history and prognostic factors for chronic hepatitis type B.

G Fattovich1, L Brollo, G Giustina, F Noventa, P Pontisso, A Alberti, G Realdi, A Ruol.   

Abstract

One hundred and five hepatitis B surface antigen (HBsAg) positive patients presenting with chronic persistent hepatitis (n = 46) or chronic active hepatitis without cirrhosis (n = 59) were followed longitudinally for one to 16 years (mean 5.5 years) and underwent follow up biopsy. During a mean histological follow up of 3.7 years, active cirrhosis developed in 21 (20%) patients one to 13 years after entry to the study with a calculated annual incidence of 5.9%. The probability of evolution to cirrhosis was significantly higher in patients with chronic active hepatitis and bridging hepatic necrosis than in those with moderate chronic active hepatitis or chronic persistent hepatitis (p less than 0.0001). Cox multiple regression analysis showed that the following three variables independently implied poor prognosis: older age, presence of bridging hepatic necrosis, and persistence of hepatitis B virus DNA in serum (p less than 0.0001). These findings indicate that patients with severe chronic active hepatitis and persistent hepatitis B virus replication are at very high risk of rapid progression to cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013423      PMCID: PMC1378837          DOI: 10.1136/gut.32.3.294

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  21 in total

1.  Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

Authors:  W F Carman; M R Jacyna; S Hadziyannis; P Karayiannis; M J McGarvey; A Makris; H C Thomas
Journal:  Lancet       Date:  1989-09-09       Impact factor: 79.321

2.  Natural history of hepatitis-associated antigen-positive chronic liver disease.

Authors:  F J Dudley; P J Scheuer; S Sherlock
Journal:  Lancet       Date:  1972-12-30       Impact factor: 79.321

3.  Natural history of liver disease in chronic hepatitis B surface antigen carriers. Survey of 100 patients from Great Britain.

Authors:  L A Viola; I G Barrison; J C Coleman; F J Paradinas; J L Fluker; B A Evans; I M Murray-Lyon
Journal:  Lancet       Date:  1981-11-21       Impact factor: 79.321

4.  The natural course of hepatitis B surface antigen-positive chronic active hepatitis in Taiwan.

Authors:  K J Lo; M J Tong; M C Chien; Y T Tsai; Y F Liaw; K C Yang; H Chian; H C Liu; S D Lee
Journal:  J Infect Dis       Date:  1982-08       Impact factor: 5.226

5.  Chronic persistent hepatitis: serological classification and meaning of the hepatitis B e system.

Authors:  J Aldershvile; O Dietrichson; P Skinhøj; P Kryger; L R Mathiesen; P Christoffersen; J O Nielsen
Journal:  Hepatology       Date:  1982 Mar-Apr       Impact factor: 17.425

6.  Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection.

Authors:  G Realdi; A Alberti; M Rugge; F Bortolotti; A M Rigoli; F Tremolada; A Ruol
Journal:  Gastroenterology       Date:  1980-08       Impact factor: 22.682

7.  Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus.

Authors:  S J Hadziyannis; H M Lieberman; G G Karvountzis; D A Shafritz
Journal:  Hepatology       Date:  1983 Sep-Oct       Impact factor: 17.425

8.  Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes.

Authors:  M Mondelli; G M Vergani; A Alberti; D Vergani; B Portmann; A L Eddleston; R Williams
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

9.  Age-specific prevalence and significance of hepatitis B e antigen and antibody in chronic hepatitis B virus infection in Taiwan: a comparison among asymptomatic carriers, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.

Authors:  Y F Liaw; C M Chu; D Y Lin; I S Sheen; C Y Yang; M J Huang
Journal:  J Med Virol       Date:  1984       Impact factor: 2.327

10.  Long-term follow-up of chronic active hepatitis of moderate severity.

Authors:  J De Groote; J Fevery; L Lepoutre
Journal:  Gut       Date:  1978-06       Impact factor: 23.059

View more
  67 in total

1.  Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology.

Authors:  J Devlin; J O'Grady
Journal:  Gut       Date:  1999-12       Impact factor: 23.059

Review 2.  Treatment of chronic hepatitis B: new antiviral therapies.

Authors:  F Yao; R G Gish
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

3.  Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection.

Authors:  Hui-Fang Hung; Hsiu-Hsi Chen
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

4.  Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.

Authors:  Helen Dakin; Morris Sherman; Scott Fung; Carrie Fidler; Anthony Bentley
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

5.  Thrombocytopenia is more severe in patients with advanced chronic hepatitis C than B with the same grade of liver stiffness and splenomegaly.

Authors:  Kazuaki Tejima; Ryota Masuzaki; Hitoshi Ikeda; Haruhiko Yoshida; Ryosuke Tateishi; Yosuke Sugioka; Yukio Kume; Tomoko Okano; Tomomi Iwai; Hiroaki Gotoh; Sachiko Katoh; Atsushi Suzuki; Yukako Koike; Yutaka Yatomi; Masao Omata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2010-03-26       Impact factor: 7.527

6.  Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.

Authors:  A Grieco; M Pompili; G Caminiti; L Miele; M Covino; B Alfei; G L Rapaccini; G Gasbarrini
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

7.  Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.

Authors:  Giada Sebastiani; Alessandro Vario; Maria Guido; Alfredo Alberti
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

8.  Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma.

Authors:  Myron J Tong; Lawrence M Blatt; Jia-Horng Kao; Jason Tzuying Cheng; William G Corey
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

Review 9.  Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies.

Authors:  Cristina Della Corte; Alessio Aghemo; Massimo Colombo
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

10.  Characteristics of treatment naïve chronic hepatitis B in Bangladesh: younger populations are more affected; HBeAg-negatives are more advanced.

Authors:  Shanhinul Alam; Nooruddin Ahmad; Golam Mustafa; Khorshed Alam; Mobin Khan
Journal:  Saudi J Gastroenterol       Date:  2008-01       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.